
Intuitive Surgical (ISRG) received a 77% rating from Validea's Martin Zweig Growth Investor model, which targets growth stocks with persistent accelerating earnings and sales growth, reasonable valuations, and low debt. As a large-cap medical equipment stock, ISRG passed several key growth and debt criteria, but notably failed on its P/E ratio, current quarter EPS growth relative to prior three quarters, and earnings persistence, resulting in a score below the 80% threshold typically signaling strategy interest.
Intuitive Surgical (ISRG) scores a 77% based on Validea's Martin Zweig-based Growth Investor model, placing it just below the 80% threshold that typically signals strategic interest. The analysis reveals a company with strong underlying growth characteristics but notable red flags. On the positive side, ISRG passes key criteria for sales growth, current and long-term earnings growth, and maintains a low total debt/equity ratio. It also shows a positive signal for insider transactions. However, the model flags significant concerns, most notably a failure on the P/E ratio, indicating the stock's valuation is considered high. Critically for a growth-focused strategy, ISRG also fails on "Earnings Persistence" and shows a recent deceleration in earnings momentum, with current quarter EPS growth not surpassing the rate of the prior three quarters. This presents a conflicting picture of a fundamentally strong growth company whose premium valuation and slowing near-term earnings acceleration are causes for caution.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.40
Ticker Sentiment